Expansion of Therapeutic and Diagnostic Drug Pipelines
First written in FY2016. 13 of 22 entries say "Advanced", first in FY2017. Latest entry: 2026-08-26.
The whole theme swung hardest in 2025: 1 of 11 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- 2026-08-26AdvancedOccurring Fact
「The animal testing phase of this study, consisting of dosing and observation, was completed as planned. No serious abnormalities were reported in general observations of the animals during the study period.」
For the anti-HIV antibody development program, the animal testing phase of the GLP-compliant repeated-dose toxicity study was completed as planned. The final study report, TK and ADA analyses, and histopathological examinations remain incomplete, and final assessments such as NOAEL have not been determined, but preparations toward the start of clinical trials are progressing as planned. - FY2026AdvancedAnnual report
「IND-enabling studies for an HIV treatment are progressing smoothly under CURED’s leadership. The company plans to begin constructing a master cell bank for antibody-producing cells during the 45th fiscal year, begin manufacturing clinical-trial materials and submit a clinical trial notification to the PMDA during the 46th fiscal year. Details will not be disclosed.」
Anti-HIV antibody development has progressed with IND-enabling studies led by CURED, and specific milestones have been presented: beginning construction of a master cell bank during the 45th fiscal year, followed by the start of clinical-trial material manufacturing and submission of a clinical trial notification to the PMDA during the 46th fiscal year. - 2026-06-15AdvancedTimely disclosure
「With support from AMED※1, CURED is conducting a GLP-compliant nonclinical toxicity study, consisting of a 4-week repeated-dose toxicity study and a 4-week recovery study in monkeys. At present, all work is progressing smoothly without any issues. The Company plans to begin constructing a master cell bank※2 for antibody-producing cells during the current fiscal year, start manufacturing the investigational drug during the 46th fiscal year, and submit a clinical trial notification to PMDA.」
For the anti-HIV antibody development program, the Company provided an update on CURED’s GLP-compliant nonclinical toxicity study and specified the next steps of constructing a master cell bank, manufacturing the investigational drug, and submitting a clinical trial notification to PMDA. The canonical thread has not been changed. - FY2025AdvancedAnnual report
「The Group aims to expand revenue, stabilize its financial position and achieve an early return to shareholders through the following initiatives: ① full-scale entry into the large diagnostic pharmaceutical market; ② expansion of the overseas research reagent market; ③ selective and focused investment in pharmaceutical seed development costs; and ④ returning unprofitable businesses to profitability.」
The company has identified entry into the diagnostic pharmaceutical market, expansion of overseas research reagents, selective and focused investment in pharmaceutical seed development, and returning unprofitable businesses to profitability as its medium- to long-term initiatives. It has reported progress on multiple diagnostic product programs toward approval, notification and sales. - FY2024AdvancedAnnual report
「Through joint development with Tokushima University, a national university corporation, the company is developing antibody therapeutics for diagnosing and treating GIST (gastrointestinal stromal tumor), a type of sarcoma thought to originate from immature mesenchymal cells beneath the mucosa of the stomach and intestinal walls, and aims to license out the program to pharmaceutical companies and other parties. It has obtained a patent in Japan for “c-KIT-Positive Tumor-Specific Antibody Fragment” (see the 4 April 2024 announcement, “Notice Regarding Patent Acquisition”) and is discussing the matter with potential partners.」
The GIST diagnostic and therapeutic antibody in the pharmaceutical pipeline obtained a patent in Japan, and the company progressed to the stage of discussions with potential partners. - FY2023AdvancedAnnual report
「Through joint development with Tokushima University, a national university corporation, the company is developing antibody therapeutics for diagnosing and treating GIST (gastrointestinal stromal tumor), a type of sarcoma thought to originate from immature mesenchymal cells beneath the mucosa of the stomach and intestinal walls, and aims to license out the program to pharmaceutical companies and other parties. It has completed a patent application and is preparing for preclinical trials.」
In its pharmaceutical pipeline, the company completed a patent application for an antibody for diagnosing and treating GIST and progressed to the preparation stage for preclinical trials. - FY2023-Q3ReframedAnnual report
「Following the change in the anti-HIV antibody manufacturing method from a genetically modified silkworm production system to a CHO cell production system, CURED is currently leading the continued development. In the fiscal year ending March 2023, the company is focusing on the development, manufacture and sale of in vitro diagnostic products and related raw materials, while pursuing a global strategy using social networking services and working to achieve a return to profitability in consolidated operating income.」
Anti-HIV antibody development changed from a genetically modified silkworm production system to a CHO cell production system and is continuing under CURED’s leadership, while the company itself has shifted its focus to in vitro diagnostic products and related raw materials. - FY2022-Q2RestatedAnnual report
「Meanwhile, development expenses increased because the company is focusing on developing in vitro diagnostic products and raw materials for such products.」
The company continues its policy of focusing on the development of in vitro diagnostic products and their raw materials. - FY2021AdvancedAnnual report
「(a) The company established the joint venture AI Bio with Abcontek of South Korea and is jointly developing ACT101, an antibody therapeutic candidate for treating SFTS, a tick-borne infectious disease. It is currently constructing a production cell line suitable for manufacturing using external sources. Going forward, it will pursue research and development and out-licensing activities with a view to licensing out the program. At present, SFTS can only be treated symptomatically, and fatalities have occurred, while no effective drugs or vaccines have been developed.\n(b) In collaboration with Tokushima University, a national university corporation, the company will research and develop antibody therapeutics for diagnosing and treating GIST (gastrointestinal stromal tumor), a type of sarcoma thought to originate from immature mesenchymal cells beneath the mucosa of the stomach and intestinal walls. It aims to license out the program to pharmaceutical companies and other parties.」
The company reported specific pipeline developments consisting of AI Bio’s joint development of an SFTS antibody candidate and construction of a production cell line, as well as research and development with Tokushima University of antibodies for diagnosing and treating GIST. - FY2021-Q3AdvancedAnnual report
「The joint venture’s future activities are planned to focus on developing pharmaceuticals, diagnostic products and other products for emerging infectious diseases, in addition to SFTS and COVID-19.」
The company presented a specific expansion of its therapeutic and diagnostic pharmaceutical pipeline through the joint venture’s development of antibody therapeutics and diagnostic products targeting SFTS, COVID-19 and emerging infectious diseases. - FY2020AdvancedAnnual report
「The company released the in vitro diagnostic products “Tau Protein-IBL” and “pTau Protein-IBL” on 7 November 2019.」
In its pharmaceutical and diagnostic pipeline, the company released in vitro diagnostic products for tau and phosphorylated tau. It also submitted an application for approval of CTP, with multiple programs reported as having progressed toward commercialization. - FY2020-Q2AdvancedAnnual report
「The company has completed the joint filing of a domestic patent application relating to “Anti-HIV Antibody and Method for Producing Same” (see the 17 September 2019 disclosure, “Notice Regarding Patent Application for ‘Anti-HIV Antibody and Method for Producing Same’”). The research is making steady progress toward results.」
For biopharmaceutical development, including anti-HIV antibodies, the company completed the joint filing of a domestic patent application and reported specific progress toward research results. - FY2020-Q1AdvancedAnnual report
「The results of the efficacy and pharmacology studies are currently being compiled, and the company aims to disclose them during the first half of the fiscal year ending March 2020.」
Development of biopharmaceuticals, including anti-HIV antibodies, progressed to the stage of compiling the efficacy and pharmacology study results and aiming to disclose them during the first half of the fiscal year ending March 2020. - FY2019RestatedAnnual report
「To further strengthen its therapeutic and diagnostic pharmaceutical pipelines, the Group plans to promote research by recruiting talented personnel in addition to its existing university and other joint research partners. It also plans to actively identify promising seeds held by overseas companies.」
The company continues its policy of expanding its therapeutic and diagnostic pharmaceutical pipeline through joint research with universities and other institutions, recruitment of personnel, and exploration of research seeds at overseas companies. - FY2019-Q3RestatedAnnual report
「In this business, the company is developing manufacturing technologies to enable pharmaceutical production using genetically modified silkworms, with a focus on research and development. In particular, development of biopharmaceuticals involving anti-HIV antibodies is progressing smoothly.」
The company continues to develop manufacturing technology for pharmaceuticals using genetically modified silkworms and biopharmaceuticals, including anti-HIV antibodies. Although it states that anti-HIV antibody development is progressing smoothly, it presents no new specific milestones. - FY2019-Q1RestatedAnnual report
「At this stage, the Company is developing biopharmaceuticals, including anti-HIV antibodies, and the related manufacturing technology with the aim of realizing pharmaceutical manufacturing using genetically modified silkworms, with research and development as its business priority.」
The company continues to manufacture pharmaceuticals using genetically modified silkworms and develop biopharmaceuticals, including anti-HIV antibodies, as well as related manufacturing technologies. - FY2018-Q1AdvancedAnnual report
「As announced on 26 June 2017, the Company entered into a joint development agreement with トランスジェニック社 (TG). Using model mice owned by TG, the parties will evaluate the efficacy and safety of an Aβ toxic oligomer-specific antibody as an AD treatment, jointly examine its potential for development as a pharmaceutical product, and seek to out-license it to a pharmaceutical manufacturer at an early stage as an AD therapeutic drug seed.」
Regarding the expansion of therapeutic drug seeds, the Company describes concrete progress, including the execution of a joint development agreement with TG concerning an Aβ toxic oligomer-specific antibody and the evaluation and potential out-licensing of the antibody as an AD treatment. - FY2017AdvancedAnnual report
「The Company jointly developed a kit to measure a causative protein for the diagnosis of Alzheimer’s disease with an overseas company and began selling it in Europe as an in vitro diagnostic product. Going forward, it will work to establish stable manufacturing.」
The Alzheimer’s disease diagnostic kit began being sold in Europe as an in vitro diagnostic product. The Company is also advancing sales of research-use measurement kits for toxic conformer antibodies and the out-licensing of therapeutic drug seeds. - FY2017-Q3RestatedAnnual report
「In this business, the Company is actively developing new therapeutic drug seeds and in vitro diagnostic products.」
The Company has reiterated its policy of actively advancing the development of new therapeutic drug seeds and in vitro diagnostic products. - FY2017-Q2RestatedAnnual report
「In this business, the Company is actively developing new therapeutic drug seeds and in vitro diagnostic products.」
The Company has reiterated its policy of actively advancing the development of new therapeutic drug seeds and in vitro diagnostic products. - FY2017-Q1RestatedAnnual report
「In this business, the Company is also actively developing new therapeutic drug seeds and in vitro diagnostic products.」
The Company has reaffirmed its policy of actively advancing the development of new therapeutic drug seeds and in vitro diagnostic products. - FY2016First statedAnnual report
「To further strengthen its therapeutic and diagnostic pharmaceutical pipelines, the Group plans to promote research by recruiting talented personnel in addition to its existing university and other joint research partners. It also plans to actively identify promising seeds held by overseas companies.」
The Company has indicated its intention to expand the pipeline through joint research with universities, recruitment of personnel and identification of seeds held by overseas companies.